The Food and Drug Administration has approved Impax Laboratories Inc.’s Abbreviated New Drug Application for a generic version of Prilosec.
Prilosec is marketed by AstraZeneca for the treatment of duodenal/gastric ulcers and gastro-esophageal reflux disease (GERD).
The new approval is for 40-mg delayed-release capsules.
Prilosec is not without serious side effects.
Subscribe to:
Post Comments (Atom)
PPI News
Posts
0 comments:
Post a Comment